Analysts have been eager to weigh in on the Healthcare sector with new ratings on Esperion (ESPR – Research Report) and Masimo (MASI – Research Report).
Esperion (ESPR)
Bank of America Securities analyst Jason Zemansky reiterated a Hold rating on Esperion on March 22 and set a price target of $2.90. The company’s shares closed last Friday at $2.29.
According to TipRanks.com, Zemansky is a 5-star analyst with an average return of
Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $7.82.
See Insiders’ Hot Stocks on TipRanks >>
Masimo (MASI)
Masimo received a Buy rating and a $160.00 price target from Wells Fargo analyst Vik Chopra today. The company’s shares closed last Friday at $134.93.
According to TipRanks.com, Chopra is a 2-star analyst with an average return of
Masimo has an analyst consensus of Moderate Buy, with a price target consensus of $135.50, which is a 1.9% upside from current levels. In a report issued on March 22, BTIG also reiterated a Buy rating on the stock with a $145.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ESPR:
- U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- Esperion: FDA approves broad new labels for NEXLETOL and NEXLIZET
- CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
- Esperion reports CHMP issues positive opinions on Nilemdo and Nustendi
- Jefferies sees Esperion takeout potential rising after near-term catalysts
